YKYasin Kalpakci

Yasin Kalpakci

*This is an algorithmically generated author record based on publicly available information.

Yasin Kalpakci has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • SARS-CoV-2 Infection in Patients with Chronic Myeloid Leukemia: A Multicenter Retrospective Study

    by Gülden Sincan, Yasin Kalpakçı, Engin Kelkitli, Fuat Erdem, Esra Altıntaş Kuşkapan, Mete Erdemir, Aysu Timuroğlu

  • Effects on mortality of early vs late administration of convalescent plasma in the treatment of Covid-19

    by Havva Kocayiğit, Gürkan Demir, Alper Karacan, Kezban Özmen Süner, Yakup Tomak, Selçuk Yaylacı, Hamad Dheir, Yasin Kalpakci, Ali Fuat Erdem


  • The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study

    by Muzeyyen Aslaner Ak, Birsen Sahip, Ayfer Geduk, Mehmer Ali Ucar, Hacer Kale, Tugba Hacibekiroglu, Merve Gokcen Polat, Yasin Kalpakci, Ali Zahit Bolaman, Birol Guvenc, et al.

    This study aimed to evaluate the clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndromes (MDS) in the real-life setting. A total of 204 patients with low-risk or intermediate-1-risk MDS who received epoetin alfa or darbepoetin alfa were included. Hemoglobin levels and transfusion need were recorded before and during 12-month treatment. Hemoglobin levels were significantly higher at each follow up visit when compared to baseline levels in both epoetin alfa (mean ± SD 8.68 ± 1.0 g/dL at baseline vs. 9.83 ± 1.45, 9.99 ± 1.55, 10.24 ± 1.77 and 10.2 ± 1.5 g/dL, respectively) and darbepoetin alfa (8.83 ± 1.09 g/dL at baseline vs. 9.62 ± 1.37, 9.78 ± 1.49, 9.9 ± 1.39 and 10.1 ± 1.5 g/dL, respectively) groups (p < 0.001 for each). Transfusion need significantly decreased from baseline at each study visit in the epoetin alfa group (p < 0.001) and only at the 12th month visit (p < 0.001) in the darbepoetin alfa group. Hemoglobin levels or transfusion need was similar between treatment groups. Overall, 12-month response rate was 58.1% for epoetin alfa and 41.9% for darbepoetin alfa, with no significant difference between treatment groups, whereas higher response rate was noted within the first three months (62.7%) compared to next 9 months (ranged 44.4–60%) of treatment in the epoetin alfa group (p ranged 0.002 to < 0.001). This real-life retrospective study revealed similar efficacy of epoetin alfa and darbepoetin alfa among low risk or intermediate-1 risk MDS patients with no difference in treatment response between treatment groups, whereas a likelihood of earlier treatment response in the epoetin alfa group.


  • Open Access

    The evaluation of patients with essential thrombocythemia in terms of risk of thrombosis

    by Cenk Sunu, Ahmet Kursad Gunes, Gulten Korkmaz Akat, Yasin Kalpakci, Funda Ceran, Simten Dagdas, Gulsum Ozet

    OBJECTIVE: The aim of this study was to compare the incidence of factors associated with an increased risk of thrombosis in patients with essential thrombocythemia. METHODS: A total of 200 patients followed-up in our unit with a diagnosis of essential thrombocythemia in 13 years were analyzed retrospectively. RESULTS: Of the study participants, 60.5% were females and 39.5% were males, with an overall mean (+/- SD) age of 54.93 (+/- 14.21) years. In 119 patients, Janus Kinase 2 was positive with 56.3% of cases. When two patient categories were defined as those with or without history of thrombosis, no significant differences were found in terms of Janus Kinase 2 positivity, mean age, as well as white blood cells and platelet counts (p>0.05). Also, no significant differences in thrombotic event incidence were found between patient categories defined on the basis of cut-off values for white blood cells (cut-off values of 15x10(3)/mm(3) and 8.7x10(3)/mm(3)) and platelets (cut-off values of 1500x10(3)/mm(3)) (p>0.05). CONCLUSION: Although our results are generally in line with the published data, some divergence from previous results has been observed with respect to risk factors for thrombotic events. Absence of a correlation between leukocytosis and thrombosis may be related with the significant decline in white blood cells after treatment. Also, a significant reduction in platelet counts occurring in association with treatment is linked with a lowered incidence of thrombosis. Janus Kinase 2-positive patients had a similar thrombosis frequency with that reported in the literature.


  • Open Access

    Efficacy of convalescent plasma according to blood groups in COVID-19 patients

    by Tuba Hacibeki̇roğlu, Yasin Kalpakçi, Ahmet Cihat Genç, İlhan Hacibeki̇roğlu, Cenk Sunu, Adem Saricaoğlu, Yakup Tomak, Oğuz Karabay, Mehmet Köroğlu

    Background/aim: In this study, we aim to investigate the efficacy of convalescent plasma (CP) according to blood groups (BGs) in the treatment of critically ill patients diagnosed with COVID-19. Materials and methods: Twenty-eight critically ill and laboratory-confirmed COVID-19 patients who were admitted to the intensive care unit (ICU) of Sakarya University, Medical Faculty were included in the study. Patients were divided into 2 groups: patients who received anti-A antibody (Ab) containing CP (BG O and B) and those who did not receive CP containing anti-A Ab (BG A and AB). Results: Among the 28 patients, 13 patients received anti-A Ab containing CP (BG; B: 6, O: 7) and 15 patients did not receive anti-A Ab CP (BG; A: 13, AB: 2). Duration in ICU, the rates of mechanical ventilation (MV) support and vasopressor support, the case fatality rate, and the discharge rate were lower in patients who received CP containing anti-A Ab than not containing anti-A Ab CP. However, only the difference in the rate of MV support achieved statistically significance (P = 0.04) Conclusion: In our study, it was observed that the efficiency of CP without anti-A antibody was lower than that of plasma containing anti-A antibody, although it was not statistically significant. This result is thought to be due to the anti-A antibody's ability to block the ACE2 receptor. We believe that this hypothesis should be investigated in controlled studies with higher patient numbers.


  • Open Access

    Comparative evaluation of memory T cells in COVID-19 patients and the predictive role of CD4+CD8+ double positive T lymphocytes as a new marker

    by Yasin Kalpakci, Tuba Hacibekiroglu, Gulay Trak, Cengiz Karacaer, Taner Demirci, Havva Kocayigit, Cenk Sunu, Ceyhun Varim, Mesude Falay

    SUMMARY BACKGROUND: The COVID-19 pandemic has affected the entire world, posing a serious threat to human health. T cells play a critical role in the cellular immune response against viral infections. We aimed to reveal the relationship between T cell subsets and disease severity. METHODS: 40 COVID-19 patients were randomly recruited in this cross-sectional study. All cases were confirmed by quantitative RT-PCR. Patients were divided into two equivalent groups, one severe and one nonsevere. Clinical, laboratory and flow cytometric data were obtained from both clinical groups and compared. RESULTS: Lymphocyte subsets, CD4+ and CD8+ T cells, memory CD4+ T cells, memory CD8+ T cells, naive CD4+ T cells, effector memory CD4+ T cells, central memory CD4+ T cells, and CD3+CD4+ CD25+ T cells were significantly lower in severe patients. The naive T cell/CD4 + EM T cell ratio, which is an indicator of the differentiation from naive T cells to memory cells, was relatively reduced in severe disease. Peripheral CD4+CD8+ double-positive T cells were notably lower in severe presentations of the disease (median DP T cells 11.12 µL vs 1.95 µL; p< 0.001). CONCLUSIONS: As disease severity increases in COVID-19 infection, the number of T cell subsets decreases significantly. Suppression of differentiation from naive T cells to effector memory T cells is the result of severe impairment in adaptive immune functions. Peripheral CD4+CD8+ double-positive T cells were significantly reduced in severe disease presentations and may be a useful marker to predict disease severity.


  • Convalescent (Immune) Plasma Therapy in the Treatment of Critical Patients Infected with SARS-Cov-2 Virus

    by Tuba Hacibeki̇roğlu, Tuğçe Nur YİĞENOĞLU, Yasin Kalpakci

    Çin Halk Cumhuriyeti’nin Wuhan Eyaletinde yarasadan insana bulaş yolu ile tesbit edilen coronavirüs ailesinden Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virüsü çok hızlı bir yayılım göstererek çok kısa bir sürede tüm dünyada etkisini göstermiştir. 11 Şubat 2020 tarihinde bu virüsün yol açtığı hastalığı COVİD-19 olarak adlandıran Dünya Sağlık Örgütü (WHO) 11 Mart 2020 tarihinde bu salgın hastalığı pandemi olarak ilan etmiştir. Konvelesan plazma (KP) tedavisi tarihteki salgın hastalık dönemlerinde kullanılmış, etkili olduğu gösterilmiş bir pasif antikor tedavisidir. Konvelesan plazmanın etki mekanizmaları arasında virüsü direkt bağlayarak nötrolize etmek, kompleman aktivasyonu, antikor bağımlı sellüler sitotoksisite ve/veya fagositoz yollarıyla virüs eliminasyonunu başlatmak sayılabilir. Nötralizan antikorlar bu etki mekanizmalarında çok önemlidir. Virüsü inaktive ederek viral replikasyonu engellemesi iyileşmedeki en önemli noktadır. Bu yüzden KP da nötrolizan antikor titresi ölçümü önemlidir. Nötralizan olmayan antikorların viral replikasyonu durdurmadığı in vitro olarak gösterilmiş ve bu antikorların proflakside kullanılabileceği, iyileşmede destekleyici etkileri olduğu öne sürülmüştür. COVİD-19 hastalığında yapılan çalışmalarda da KP nın etkili olduğu görülmüştür. Ülkemizde ve Amerikada yakın zamanda tedavi endikasyonu alan bu tedavi yönteminin uygulama kriterleri her iki ülke tarafından belirlenmiştir. Uygun donorlerden, fayda görebilecek hastalara nakledilen konvelesan plazma tedavi sonuçları merakla beklenmektedir.